Hanmi Pharmaceutical agrees to mega-license dealHanmi Pharmaceutical entered into an agreement with Sanofi, a French drug maker, to license the Korean company’s Quantum Project, a diabetes solutions portfolio in development, Hanmi said Thursday.
Hanmi will receive an upfront payment of 400 million euros ($435 million) and is eligible for payments of up to 3.5 billion euros, according to certain sales and development milestones. After the product is released, a separate two-digit percentage royalty for the sales will also be provided to the Korean drug maker.
Sanofi will receive a worldwide license to develop and commercialize three investigative diabetes treatments, including a drug called efpeglenatide that belongs to a novel class of medicines called GLP1-agnostics, used to control blood sugar.
Hanmi will keep an exclusive option to jointly commercialize the products in Korea and China.
The Quantum Project is a new pipeline of a long lasting-diabetes treatment applying Hanmi’s technology, LAPSCOVERY (Long Acting Protein/Peptide Discovery), which maximizes treatment by limiting the number and dose of administered medicines.
BY KIM JEE-HEE, BLOOMBERG [firstname.lastname@example.org]
More in Industry
Move over Federer
Hanjin KAL slams largest shareholder, accusing it of peddling lies
Tech firms brief president on state of AI research
Dongsuh recognizes female authors at Scent of Life Awards